2211082-53-8
Chemical Structure
Gunagratinib
Synonym(s): ICP-192
- CAS No.: 2211082-53-8
- Formula:C22H25N5O4
- Molecular Weight:423.47
IUPAC Name: (S)-1-(1-acryloylpyrrolidin-3-yl)-3-((3,5-dimethoxyphenyl)ethynyl)-5-(methylamino)-1H-pyrazole-4-carboxamide
InChIKey: QFUIJOBJAQBGDH-HNNXBMFYSA-N
SMILES: CNC1=C(C(N)=O)C(C#CC2=CC(OC)=CC(OC)=C2)=NN1[C@]3([H])CN(CC3)C(C=C)=O
Biological Activity: Gunagratinib (ICP-192) is a low toxicity and orally active pan-FGFR (fibroblast growth factor receptors) inhibitor that potently and selectively inhibits FGFR activities irreversibly by covalent binding. Gunagratinib can be used for the research of cancer[1]. Gunagratinib is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Gunagratinib | 98.52% | Gunagratinib (ICP-192) is a low toxicity and orally active pan-FGFR (fibroblast growth factor receptors) inhibitor that potently and selectively inhibits FGFR activities irreversibly by covalent binding. Gunagratinib can be used for the research of cancer. Gunagratinib is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
-
Similarity Score 0.65
HY-100818Futibatinib -
Similarity Score 0.59
HY-147621FGFR-IN-6 -
Similarity Score 0.54
HY-156632Resigratinib -
Similarity Score 0.51
HY-149051BGB-8035 -
Similarity Score 0.50
HY-101766Btk inhibitor 2 -
Similarity Score 0.47
HY-147619FGFR-IN-4 -
Similarity Score 0.45
HY-101474ARZanubrutinib (Standard) -
Similarity Score 0.45
HY-101474BR(R)-Zanubrutinib (Standard) -
Similarity Score 0.45
HY-101474R(±)-Zanubrutinib (Standard) -
Explore the MedChemAI to find more analogs
References
- [1]. Guo Ye, et al. Phase I result of ICP-192 (gunagratinib), a highly selective irreversible FGFR inhibitor, in patients with advanced solid tumors harboring FGFR pathway alterations. Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021) 4092-4092.
- [2]. Jisong Cui, et al. Method for treating head and neck cancer. WO2023088105A1. 2022-11-03